Clinical trial
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)
NCT03445650 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 18, 2018
- Completion date
- January 18, 2020
- Enrollment
- 11 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.